

Datasheet for 609-709-123

Human IgG (H&L) Antibody Texas Red™ Conjugated Pre-Adsorbed**Overview**

Description:	Donkey Anti-Human IgG (H&L) Antibody Texas Red™ Conjugated (Min X Bv Ch Gt GP Ham Hs Ms Rb Rt & Sh Serum Proteins) - 609-709-123
Item No.:	609-709-123
Size:	1 mg
Applications:	IHC
Reactivity:	Human
Host Species:	Donkey

Product Details

Background:	Anti-Human IgG (H&L) Texas Red generated in donkey detects human Immunoglobulin G (IgG), both heavy and light chains of the antibody molecule are present. It is a protein complex composed of four peptide chains — two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. Each IgG has two antigen binding sites. Representing approximately 75% of serum immunoglobulins in humans, IgG is the most abundant antibody isotype found in the circulation. IgG molecules are synthesized and secreted by plasma B cells. Secondary Antibodies are available in a variety of formats and conjugate types. When choosing a secondary antibody product, consideration must be given to species and immunoglobulin specificity, conjugate type, fragment and chain specificity, level of cross-reactivity, and host-species source and fragment composition.
Synonyms:	Donkey Anti Human IgG Texas Red™ Conjugated Antibody, Donkey Anti-Human IgG Antibody Texas Red™ Conjugation
Host Species:	Donkey
Specificity:	IgG (H&L)
Conjugate:	Texas Red®
Clonality:	Polyclonal
Format:	IgG
F/P Ratio:	4.9

Target Details

Reactivity:	Human
Immunogen:	Human IgG whole molecule
Purity/Specificity:	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Donkey Serum, Human IgG and Human Serum. No reaction was observed against Bovine, Chicken, Goat, Guinea Pig, Hamster, Horse, Mouse, Rabbit, Rat & Sheep Serum Proteins.

Application Details

Suggested Applications:	IHC (Based on references)
Application Note:	Anti-Human IgG (H&L) Texas Red is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
FC:	1:500 - 1:2,500
FLISA:	1:10,000 - 1:50,000
IF:	1:1,000 - 1:5,000

Formulation

Physical State:	Lyophilized
Concentration:	1.0 mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Reconstitution Volume:	1.0 mL
Reconstitution Buffer:	Restore with deionized water (or equivalent)


Shipping & Handling

Shipping Condition: Ambient

Storage Condition: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.


Expiration: Expiration date is one (1) year from date of receipt.

Images



Immunohistochemistry

Immunostainings with CD68 and VEGF antibodies reveal an increase in expression of both markers at 3 and 7d post operation followed by a decline at d14 and d28. Bevacizumab treatment leads to a reduction of CD68+ cells at d14 and d28 (a). (dashed line: distal tendon stump; asterisk: dermis; scale bar: 200µm). Bevacizumab is detectable 3d after injection at 4d p.o. (c), but not at 14d p.o. (d). Upon injection at 4 and 11d p.o., Bevacizumab is detectable at 14d p.o. (e). In the vehicle injected tendon, no Bevacizumab is detectable (b). Fig 2. PMID: 29672303.



Immunohistochemistry

Quantitative analysis of immunofluorescence images shows the capability of Bevacizumab to reduce RecA1+ vessels and CD68-positive cells at 14 and 28d p.o. (a,d), illustrated by representative images (b,c) dashed line: proximal tendon stump. By trend, also the average vessel diameter is reduced in the Bevacizumab group after 28d (e). The density of Podoplanin+ lymphatic vessels is not affected by Bevacizumab (f), as illustrated by representative images taken from the newly formed repair tissue (g,h). Fig 3. PMID: 29672303.

References

- Tempfer et al. Bevacizumab Improves Achilles Tendon Repair in a Rat Model. *Cellular Physiology and Biochemistry* (2018)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.